Close Menu

antibody arrays

The Next Test

The Los Angeles Times writes that another coronavirus testing challenge — antibody testing — looms. 

The Swedish molecular diagnostics firm will use the proceeds, in part, to fund the planned launch of its Immray PanCan-d assay for detecting pancreatic cancer.

Over the next three years, Immunovia and its partners will use the firm's Immray PanCan-d assay to screen 6,000 diabetes patients for pancreatic cancer.

The company said that it can distinguish patients suffering from lupus from those with other autoimmune diseases using its antibody array platform.

SMiLE-seq combines antibody arrays, mechanical trapping, and next-generation sequencing readouts to provide a new platform for characterizing DNA-protein interactions.

The study, called Panfam-1, will analyze 1,000 individuals at high risk of familial pancreatic cancer over three years using the company's antibody array test.

Translational scientist Jacqueline Achkar of Albert Einstein Medical College will lead several collaborations to build a point-of-care diagnostic platform.

The firm is developing tests based on its microarray technology, which is capable of printing multiple types of biomarkers.

The Swedish firm, a spinout of Lund University, will evaluate the array-based blood tests to confirm, rule out, and monitor the autoimmune disease.

The microcapillary-based single-cell platform is designed to analyze antibodies but could be used to detect other cell products.

Pages

The Washington Post reports that the CDC's SARS-CoV-2 test issues reflect earlier ones it had with Zika virus testing.

NPR writes that even with thousands of new COVID-19 papers, each should be evaluated based on its own quality.

Researchers traced a gene cluster linked to COVID-19 severity to Neanderthals, the New York Times reports.

In PNAS this week: soil bacteria-derived small molecules affect centrosomal protein, microfluidics approach for capturing circulating tumor cells, and more.